 | • レポートコード：MRC2304J0115 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、247ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、世界の子宮頸がん治療薬市場規模は、2021年6,920.92百万ドルから2022年に7,263.09百万ドルへと拡大、その後2027年までに年平均5.12％成長して9,338.97百万ドルに達する見通しです。本書は、子宮頸がん治療薬の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別分析（高度浸潤期、初期浸潤期、前悪性病変）、治療タイプ別分析（化学療法、コールドナイフ円錐生検、円錐生検、凍結療法、ホルモン療法）、エンドユーザー別分析（診断センター、病院、緩和ケアクリニック、薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目を掲載しています。なお、本書には、Amgen Inc、AstraZeneca、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、Genentech, Inc.、Genmab A/S、GlaxoSmithKline plc、Johnson & Johnson、Merck & Co. Inc、Novartis AG、Pfizer Incなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の子宮頸がん治療薬市場規模：疾患別 - 高度浸潤期の市場規模 - 初期浸潤期の市場規模 - 前悪性病変の市場規模 ・世界の子宮頸がん治療薬市場規模：治療タイプ別 - 化学療法の市場規模 - コールドナイフ円錐生検の市場規模 - 円錐生検の市場規模 - 凍結療法の市場規模 - ホルモン療法の市場規模 ・世界の子宮頸がん治療薬市場規模：エンドユーザー別 - 診断センターにおける市場規模 - 病院における市場規模 - 緩和ケアクリニックにおける市場規模 - 薬局における市場規模 ・世界の子宮頸がん治療薬市場規模：地域別 - 南北アメリカの子宮頸がん治療薬市場規模 アメリカの子宮頸がん治療薬市場規模 カナダの子宮頸がん治療薬市場規模 ブラジルの子宮頸がん治療薬市場規模 ... - アジア太平洋の子宮頸がん治療薬市場規模 日本の子宮頸がん治療薬市場規模 中国の子宮頸がん治療薬市場規模 インドの子宮頸がん治療薬市場規模 韓国の子宮頸がん治療薬市場規模 台湾の子宮頸がん治療薬市場規模 ... - ヨーロッパ/中東/アフリカの子宮頸がん治療薬市場規模 イギリスの子宮頸がん治療薬市場規模 ドイツの子宮頸がん治療薬市場規模 フランスの子宮頸がん治療薬市場規模 ロシアの子宮頸がん治療薬市場規模 ... - その他地域の子宮頸がん治療薬市場規模 ・競争状況 ・企業情報 |
The Global Cervical Cancer Drugs Market size was estimated at USD 6,920.92 million in 2021 and expected to reach USD 7,263.09 million in 2022, and is projected to grow at a CAGR 5.12% to reach USD 9,338.97 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cervical Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the market was studied across Advanced Invasive Stage, Early Invasive Stage, and Pre-malignant Lesions.
Based on Treatment Type, the market was studied across Chemotherapy, Cold Knife Cone Biopsy, Cone Biopsy, Cryotherapy, Hormone Therapy, LEEP (Loop Electrosurgical Excision Procedure), Laser Surgery, Radiation Therapy, Radical Trachelectomy, Simple Hysterectomy, and Targeted Therapy.
Based on End User, the market was studied across Diagnostic Centers, Hospitals, Palliative Care Clinics, and Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cervical Cancer Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cervical Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cervical Cancer Drugs Market, including Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Genmab A/S, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, and Pfizer Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cervical Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cervical Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cervical Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cervical Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cervical Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Cervical Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cervical Cancer Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the prevalence of cervical cancer
5.1.1.2. Government initiatives to spread awareness about cervical cancer
5.1.1.3. Development in healthcare facilities and infrastructure
5.1.1.4. Availability of novel drugs and the presence of a strong pipeline
5.1.2. Restraints
5.1.2.1. Adverse effects associated with the use of drugs and stringent regulations
5.1.3. Opportunities
5.1.3.1. Increasing research and development investment coupled with collaborations among manufacturers
5.1.3.2. Untapped emerging economies
5.1.4. Challenges
5.1.4.1. High cost and lack of availability of the drug
5.2. Cumulative Impact of COVID-19
6. Cervical Cancer Drugs Market, by Indication
6.1. Introduction
6.2. Advanced Invasive Stage
6.3. Early Invasive Stage
6.4. Pre-malignant Lesions
7. Cervical Cancer Drugs Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Cold Knife Cone Biopsy
7.4. Cone Biopsy
7.5. Cryotherapy
7.6. Hormone Therapy
7.7. LEEP (Loop Electrosurgical Excision Procedure)
7.8. Laser Surgery
7.9. Radiation Therapy
7.10. Radical Trachelectomy
7.11. Simple Hysterectomy
7.12. Targeted Therapy
8. Cervical Cancer Drugs Market, by End User
8.1. Introduction
8.2. Diagnostic Centers
8.3. Hospitals
8.4. Palliative Care Clinics
8.5. Pharmacies
9. Americas Cervical Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cervical Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cervical Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Amgen Inc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bristol-Myers Squibb Company
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Eli Lilly and Company
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. F. Hoffmann-La Roche Ltd
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Genentech, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Genmab A/S
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. GlaxoSmithKline plc
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Johnson & Johnson
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Merck & Co. Inc
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Novartis AG
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Pfizer Inc
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing